Improved Low-qubit Hidden Shift Algorithms

Hidden shift problems are relevant to assess the quantum security of various cryptographic constructs. Multiple quantum subexponential time algorithms have been proposed. In this paper, we propose some improvements on a polynomial quantum memory algorithm proposed by Childs, Jao and Soukharev in 2010. We use subset-sum algorithms to significantly reduce its complexity. We also propose new tradeoffs between quantum queries, classical time and classical memory to solve this problem

Électorat écologiste et risque industriel

En France comme dans certains pays industriels, l'écologie a émergé dans le jeu politique au début des années 1970. La courbe du vote écologiste (graphique 1) aux élections nationales indique que, après une longue période de stagnation au cours de laquelle les forces écologistes n'ont pas atteint le seuil de 5 % des suffrages exprimés, l'écologie électorale a brutalement dépassé 10 % des suffrages exprimés aux élections européennes de 1989, atteint un sommet aux élections régionales de 1992 (près de 15 %), puis à nou­veau décliné aux élections législatives de 1993 avec un score encore remarquable de 11 %1. Depuis cette date, les divisions du mouvement semblent avoir induit un nouvel affaiblissement du vote écologique. Aux élections européennes de juin 1994, les deux listes écologistes n'atteignent plus qu'un peu moins de 5 % des suffrages exprimés, soit un score voisin de celui obtenu près de quinze ans plus tôt aux élections européennes de 1979. À l'élection présidentielle de 1995, Dominique Voynet n'obtient que 3,9 % des suffrages exprimés. [Premier paragraphe

A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial

International audienceBackground : Metastatic pancreatic adenocarcinoma (PAC) prognosis remains dismal and gemcitabine monotherapy has been the standard treatment over the last decade. Currently, two first-line regimens are used in this setting: FOLFIRINOX and nab-paclitaxel plus gemcitabine. Increasing translational data on the predictive value of hENT1 for determining gemcitabine efficacy suggest that a non-gemcitabine-based regimen is favored in about 60 % of patients with PAC due to high resistance of PAC to this cytotoxic drug. This study aims to evaluate the efficacy of weekly nab-paclitaxel combined with gemcitabine or a simplified (s) LV5FU2 regimen in patients with previously untreated metastatic PAC.Methods/design : AFUGEM is a two-stage, open-label, randomized, multicenter, phase II trial. Patients with PAC who meet the inclusion criteria and provide written informed consent will be randomized in a 1:2 ratio to either nab-paclitaxel (125 mg/m 2 ) plus gemcitabine (1000 mg/m 2 ) given on days 1, 8, and 15 every 28 days or nab-paclitaxel (125 mg/m 2 ) plus sLV5FU2 (leucovorin 400 mg/m 2 followed by bolus 400 mg/m 2 5-fluorouracil and by 5-fluorouracil 2400 mg/m 2 as an 46-h intravenous infusion) given on days 1 and 15 every 28 days. A total of 114 patients will be randomized to one of the treatment arms. The primary endpoint is progression-free survival at 4 months. Secondary outcomes are rate and duration of response, disease control, overall survival, safety, and quality of life. Potential biomarkers of gemcitabine (hENT1, dCK) and 5-fluorouracil (TS) efficacy will be assessed.Discussion : The AFUGEM trial is designed to provide valuable information regarding efficacy and tolerability of nab-paclitaxel plus gemcitabine and nab-paclitaxel plus sLV5FU2 regimens. Identification of potential predictive biomarkers of gemcitabine and 5-fluorouracil is likely to drive therapeutic decisions in patients with metastatic PAC

Item response theory and factor analysis as a mean to characterize occurrence of response shift in a longitudinal quality of life study in breast cancer patients.

International audienceBACKGROUND: The occurrence of response shift (RS) in longitudinal health-related quality of life (HRQoL) studies, reflecting patient adaptation to disease, has already been demonstrated. Several methods have been developed to detect the three different types of response shift (RS), i.e. recalibration RS, 2) reprioritization RS, and 3) reconceptualization RS. We investigated two complementary methods that characterize the occurrence of RS: factor analysis, comprising Principal Component Analysis (PCA) and Multiple Correspondence Analysis (MCA), and a method of Item Response Theory (IRT). METHODS: Breast cancer patients (n = 381) completed the EORTC QLQ-C30 and EORTC QLQ-BR23 questionnaires at baseline, immediately following surgery, and three and six months after surgery, according to the "then-test/post-test" design. Recalibration was explored using MCA and a model of IRT, called the Linear Logistic Model with Relaxed Assumptions (LLRA) using the then-test method. Principal Component Analysis (PCA) was used to explore reconceptualization and reprioritization. RESULTS: MCA highlighted the main profiles of recalibration: patients with high HRQoL level report a slightly worse HRQoL level retrospectively and vice versa. The LLRA model indicated a downward or upward recalibration for each dimension. At six months, the recalibration effect was statistically significant for 11/22 dimensions of the QLQ-C30 and BR23 according to the LLRA model (p ≤ 0.001). Regarding the QLQ-C30, PCA indicated a reprioritization of symptom scales and reconceptualization via an increased correlation between functional scales. CONCLUSIONS: Our findings demonstrate the usefulness of these analyses in characterizing the occurrence of RS. MCA and IRT model had convergent results with then-test method to characterize recalibration component of RS. PCA is an indirect method in investigating the reprioritization and reconceptualization components of RS

STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer.

BACKGROUND: The management of unresectable metastatic colorectal cancer (mCRC) is a comprehensive treatment strategy involving several lines of therapy, maintenance, salvage surgery, and treatment-free intervals. Besides chemotherapy (fluoropyrimidine, oxaliplatin, irinotecan), molecular-targeted agents such as anti-angiogenic agents (bevacizumab, aflibercept, regorafenib) and anti-epidermal growth factor receptor agents (cetuximab, panitumumab) have become available. Ultimately, given the increasing cost of new active compounds, new strategy trials are needed to define the optimal use and the best sequencing of these agents. Such new clinical trials require alternative endpoints that can capture the effect of several treatment lines and be measured earlier than overall survival to help shorten the duration and reduce the size and cost of trials. METHODS/DESIGN: STRATEGIC-1 is an international, open-label, randomized, multicenter phase III trial designed to determine an optimally personalized treatment sequence of the available treatment modalities in patients with unresectable RAS wild-type mCRC. Two standard treatment strategies are compared: first-line FOLFIRI-cetuximab, followed by oxaliplatin-based second-line chemotherapy with bevacizumab (Arm A) vs. first-line OPTIMOX-bevacizumab, followed by irinotecan-based second-line chemotherapy with bevacizumab, and by an anti-epidermal growth factor receptor monoclonal antibody with or without irinotecan as third-line treatment (Arm B). The primary endpoint is duration of disease control. A total of 500 patients will be randomized in a 1:1 ratio to one of the two treatment strategies. DISCUSSION: The STRATEGIC-1 trial is designed to give global information on the therapeutic sequences in patients with unresectable RAS wild-type mCRC that in turn is likely to have a significant impact on the management of this patient population. The trial is open for inclusion since August 2013. TRIAL REGISTRATION: STRATEGIC-1 is registered at Clinicaltrials.gov: NCT01910610, 23 July, 2013. STRATEGIC-1 is registered at EudraCT-No.: 2013-001928-19, 25 April, 2013

STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer

International audienceBackground: The management of unresectable metastatic colorectal cancer (mCRC) is a comprehensive treatment strategy involving several lines of therapy, maintenance, salvage surgery, and treatment-free intervals. Besides chemotherapy (fluoropyrimidine, oxaliplatin, irinotecan), molecular-targeted agents such as anti-angiogenic agents (bevacizumab, aflibercept, regorafenib) and anti-epidermal growth factor receptor agents (cetuximab, panitumumab) have become available. Ultimately, given the increasing cost of new active compounds, new strategy trials are needed to define the optimal use and the best sequencing of these agents. Such new clinical trials require alternative endpoints that can capture the effect of several treatment lines and be measured earlier than overall survival to help shorten the duration and reduce the size and cost of trials. Methods/Design: STRATEGIC-1 is an international, open-label, randomized, multicenter phase III trial designed to determine an optimally personalized treatment sequence of the available treatment modalities in patients with unresectable RAS wild-type mCRC. Two standard treatment strategies are compared: first-line FOLFIRI-cetuximab, followed by oxaliplatin-based second-line chemotherapy with bevacizumab (Arm A) vs. first-line OPTIMOX-bevacizumab, followed by irinotecan-based second-line chemotherapy with bevacizumab, and by an anti-epidermal growth factor receptor monoclonal antibody with or without irinotecan as third-line treatment (Arm B). The primary endpoint is duration of disease control. A total of 500 patients will be randomized in a 1:1 ratio to one of the two treatment strategies.Discussion: The STRATEGIC-1 trial is designed to give global information on the therapeutic sequences in patients with unresectable RAS wild-type mCRC that in turn is likely to have a significant impact on the management of this patient population. The trial is open for inclusion since August 2013. Trial registration: STRATEGIC-1 is registered a

Improved Low-qubit Hidden Shift Algorithms

Hidden shift problems are relevant to assess the quantum security of various cryptographic constructs. Multiple quantum subexponential time algorithms have been proposed. In this paper, we propose some improvements on a polynomial quantum memory algorithm proposed by Childs, Jao and Soukharev in 2010. We use subset-sum algorithms to significantly reduce its complexity. We also propose new tradeoffs between quantum queries, classical time and classical memory to solve this problem

Improved Classical and Quantum Algorithms for Subset-Sum

We present new classical and quantum algorithms for solving random subset-sum instances. First, we improve over the Becker-Coron-Joux algorithm (EUROCRYPT 2011) from $\tilde{\mathcal{O}}(2^{0.291 n})$ downto $\tilde{\mathcal{O}}(2^{0.283 n})$, using more general representations with values in $\{-1,0,1,2\}$. Next, we improve the state of the art of quantum algorithms for this problem in several directions. By combining the Howgrave-Graham-Joux algorithm (EUROCRYPT 2010) and quantum search, we devise an algorithm with asymptotic cost $\tilde{\mathcal{O}}(2^{0.236 n})$, lower than the cost of the quantum walk based on the same classical algorithm proposed by Bernstein, Jeffery, Lange and Meurer (PQCRYPTO 2013). This algorithm has the advantage of using \emph{classical} memory with quantum random access, while the previously known algorithms used the quantum walk framework, and required \emph{quantum} memory with quantum random access. We also propose new quantum walks for subset-sum, performing better than the previous best time complexity of $\tilde{\mathcal{O}}(2^{0.226 n})$ given by Helm and May (TQC 2018). We combine our new techniques to reach a time $\tilde{\mathcal{O}}(2^{0.216 n})$. This time is dependent on a heuristic on quantum walk updates, formalized by Helm and May, that is also required by the previous algorithms. We show how to partially overcome this heuristic, and we obtain an algorithm with quantum time $\tilde{\mathcal{O}}(2^{0.218 n})$ requiring only the standard classical subset-sum heuristics

Quantum Key-Recovery on full AEZ

International audienceAEZ is an authenticated encryption algorithm, submitted to the CAESAR competition. It has been selected for the third round of the competition. While some classical analysis on the algorithm have been published, the cost of these attacks is beyond the security claimed by the designers. In this paper, we show that all the versions of AEZ are completely broken against a quantum adversary. For this, we propose a generalisation of Simon's algorithm for quantum period finding that allows to build efficient attacks